These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9061156)

  • 1. Helicobacter pylori.
    Seifrit B
    AORN J; 1997 Mar; 65(3):614-6, 619-20. PubMed ID: 9061156
    [No Abstract]   [Full Text] [Related]  

  • 2. Six months' experience with a pharmacist-run Helicobacter pylori treatment clinic.
    Patchin GM; Wieland KA; Carmichael JM
    Am J Health Syst Pharm; 1996 Sep; 53(17):2081-2. PubMed ID: 8991624
    [No Abstract]   [Full Text] [Related]  

  • 3. HELIDAC therapy (bismuth subsalicylate/metronidazole/tetracycline hydrochloride).
    Claussen DW
    Gastroenterol Nurs; 1997; 20(5):188-9. PubMed ID: 9384064
    [No Abstract]   [Full Text] [Related]  

  • 4. Eczema responsive to treatment for Helicobacter pylori.
    Wilson WH
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):290. PubMed ID: 7552934
    [No Abstract]   [Full Text] [Related]  

  • 5. Significance of a tetracycline and Pepto-Bismol interaction in the management of Helicobacter pylori-induced peptic ulcer disease.
    Tkach CL; Ariano RE
    Ann Pharmacother; 1998 Mar; 32(3):387. PubMed ID: 9533072
    [No Abstract]   [Full Text] [Related]  

  • 6. [Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori].
    García Pérez A; Valverde de La Osa J; Giménez Samper M; Alonso García I
    Sangre (Barc); 1999 Oct; 44(5):387-8. PubMed ID: 10618919
    [No Abstract]   [Full Text] [Related]  

  • 7. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
    Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
    Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model.
    Sizemore CF; Quispe JD; Amsler KM; Modzelewski TC; Merrill JJ; Stevenson DA; Foster LA; Slee AM
    Antimicrob Agents Chemother; 2002 May; 46(5):1435-40. PubMed ID: 11959579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori infection.
    Suerbaum S; Michetti P
    N Engl J Med; 2002 Oct; 347(15):1175-86. PubMed ID: 12374879
    [No Abstract]   [Full Text] [Related]  

  • 10. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.
    Peura DA; Graham DY
    Am J Gastroenterol; 1994 Aug; 89(8):1137-9. PubMed ID: 8053422
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
    Kadayifci A; Uygun A; Polat Z; Kantarcioğlu M; Kılcıler G; Başer O; Ozcan A; Emer O
    Turk J Gastroenterol; 2012 Feb; 23(1):8-13. PubMed ID: 22505373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?
    de Boer WA; Tytgat GN
    Scand J Gastroenterol; 1995 May; 30(5):401-7. PubMed ID: 7638563
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.
    Lee M; Kemp JA; Canning A; Egan C; Tataronis G; Farraye FA
    Arch Intern Med; 1999 Oct; 159(19):2312-6. PubMed ID: 10547171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the eradication of Helicobacter pylori with triple therapy.
    Graham DY; Lew GM; Malaty HM; Evans DG; Evans DJ; Klein PD; Alpert LC; Genta RM
    Gastroenterology; 1992 Feb; 102(2):493-6. PubMed ID: 1732120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori and peptic ulcer disease. Reexamining the therapeutic approach.
    Fedotin MS
    Postgrad Med; 1993 Sep; 94(3):38-40, 43-5. PubMed ID: 8361941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area.
    Vilaichone RK; Prapitpaiboon H; Gamnarai P; Namtanee J; Wongcha-um A; Chaithongrat S; Mahachai V
    Asian Pac J Cancer Prev; 2015; 16(14):6089-92. PubMed ID: 26320500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth subcitrate/metronidazole/ tetracycline--Axcan Pharma. Bismuth triple therapy--Axcan Pharma, Helicide.
    Drugs R D; 2002; 3(6):402-4. PubMed ID: 12516945
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection.
    al-Assi MT; Ramirez FC; Lew GM; Genta RM; Graham DY
    Am J Gastroenterol; 1994 Aug; 89(8):1203-5. PubMed ID: 8053435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H. pylori and ulcers.
    McGuffey EC
    Am Pharm; 1994 Jul; NS34(7):21. PubMed ID: 8085532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.